"Management is pleased to report that preliminary results of a Pharmacokinetic study conducted in dogs (beagle) by an independent Contract Research Organization, following strictly regulated protocols, using coded products with Ibuprofen formulation according to Spencer Pharmaceutical Inc. patented formulations, showed the rapid release of the active ingredient."
Ironically all this PR does is emphasise just how far away Spencer's controlled release products are from being launched in any market, if ever. Animal testing of this sort is a sine qua non for any drug candidate and needs to be followed by years of human studies costing many millions of dollars.
No respectable Pharma company would PR such an inconsequential piece of "news".
A thoroughly disreputable one like Spencer Pharma would though, presumably to distract attention from the fact that the (entirely fictional) buy-out of SPPH by Al-Dora/Al-Dorra/Al Durrah/Hail First Pharma (none of which exist outside of SPPH's fraudulent PRs) is at least 30 days behind schedule:
"Management of Spencer is keeping Al-Dorra and its subsidiary Hail First Pharma updated on these exciting new developments as they are diligently working on the buyout transactions and continuing updates are scheduled to be released to shareholders."